logo

For the Inventor, By the Inventor

Milton, MA, United States of America

Nabil El-Tayar

This inventor holds 6 USPTO granted patents. Top assignees: Applied Research Systems Ars Holding N.v., Laboratoires Serono S.a., Merck Serono S. a.. Active years: 2002-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nabil El-Tayar. Retrieved from https://idiyas.com/inventor/nabil-el-tayar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 33.3

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 66(Granted Patents)


Company Filing History:

goldMedal4 out of 156 
 
Applied Research Systems Ars Holding N.v.
 patents
silverMedal1 out of 40 
 
Laboratoires Serono S.a.
 patents
bronzeMedal1 out of 145 
 
Merck Serono S. a.
 patents

Years Active: 2002-2010

Loading Chart...
6 patents (USPTO):Explore Patents
1. 7700314 - Method for producing polyol-IFN-β conjugate (2010-04-20),
2. 7357925 - Method for treating disorders and diseases treatable with human fibroblast interferon (2008-04-15),
3. 7268210 - PEG-LHRH analog conjugates (2007-09-11),
4. 6914121 - PEG-LHRH analog conjugates (2005-07-05),
5. 6638500 - Polyol-IFN-&bgr;conjugates modified at Cys-17 and composition containing same (2003-10-28),
6. 6433135 - PEG-LHRH analog conjugates (2002-08-13),

Title: Nabil El-Tayar: Innovator in PEGylation Technology

Introduction

Nabil El-Tayar is a prominent inventor based in Milton, MA (US), known for his significant contributions to the field of biotechnology. He holds a total of 6 patents, showcasing his innovative approach to medical treatments and pharmaceutical compositions.

Latest Patents

El-Tayar's latest patents include a method for producing polyol-IFN-β conjugates, specifically PEG-IFN-β conjugates. This process involves the site-specific PEGylation of human IFN-β using a thiol-reactive PEGylating agent. His inventions provide pharmaceutical compositions and methods for treating infections, tumors, and autoimmune and inflammatory diseases. Additionally, he has developed a method for the stepwise attachment of PEG moieties in series to a polypeptide, particularly focusing on IFN-β.

Career Highlights

Throughout his career, Nabil El-Tayar has worked with notable companies such as Applied Research Systems and Merck Serono S.A. His work has significantly impacted the development of therapeutic solutions in the medical field.

Collaborations

El-Tayar has collaborated with esteemed colleagues, including Michael James Roberts and Milton Harris, contributing to advancements in his research and innovations.

Conclusion

Nabil El-Tayar's work in PEGylation technology and his numerous patents highlight his role as a key innovator in biotechnology. His contributions continue to influence the development of effective treatments for various medical conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…